<DOC>
	<DOCNO>NCT02393807</DOCNO>
	<brief_summary>The current study investigate relative bioavailability spray dry dispersion solid dose formulation PF 06260414 administer single oral dose 30 mg PF 06260414 relative single oral dose 30 mg PF 06260414 administer nanosuspension fast fed condition healthy adult subject .</brief_summary>
	<brief_title>The Bioavailability Spray Dried Dispersion Solid Dose Formulation PF-06260414 Relative Suspension Formulation</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject non childbearing potential age 18 55 year , inclusive . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Any condition possibly affect drug absorption ( eg , gastrectomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>